Ge Long Hui·2025-11-13 10:02Core Viewpoint - The company reported a significant increase in total revenue and improved gross margin for the first nine months of 2025, driven by strong sales of its core product and a licensing agreement [1] Financial Performance - Total revenue for the first nine months of 2025 reached 1.115 billion yuan, representing a year-on-year growth of 59.85% [1] - Gross margin improved to 88.8%, up from 86.0% in the same period last year, an increase of 2.8 percentage points [1] - The net loss for the same period was 72 million yuan, a reduction of 74.78% compared to the previous year [1] Product and Market Focus - The company emphasizes its strong R&D capabilities as a core driver of its business, focusing on high unmet clinical needs in oncology and autoimmune diseases [1] - The company aims to develop breakthrough innovative drugs that are either first-in-class or best-in-class in the global market [1]